BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36377657)

  • 1. STINGing the immune system: lessons learned through a model of G34-mutant pediatric high-grade glioma.
    Hall CP; Cronk JC; Rubens JA
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
    Haase S; Banerjee K; Mujeeb AA; Hartlage CS; Núñez FM; Núñez FJ; Alghamri MS; Kadiyala P; Carney S; Barissi MN; Taher AW; Brumley EK; Thompson S; Dreyer JT; Alindogan CT; Garcia-Fabiani MB; Comba A; Venneti S; Ravikumar V; Koschmann C; Carcaboso ÁM; Vinci M; Rao A; Yu JS; Lowenstein PR; Castro MG
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36125896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
    Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
    J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas.
    Garcia-Fabiani MB; Haase S; Banerjee K; McClellan B; Zhu Z; Mujeeb A; Li Y; Yu J; Kadiyala P; Taher A; Núñez FJ; Alghamri MS; Comba A; Mendez FM; Nicola Candia AJ; Salazar B; Koschmann C; Nunez FM; Edwards M; Qin T; Sartor MA; Lowenstein PR; Castro MG
    bioRxiv; 2023 Jun; ():. PubMed ID: 37398299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
    Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
    Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
    Lavrador JP; Reisz Z; Sibtain N; Rajwani K; Baig Mirza A; Vergani F; Gullan R; Bhangoo R; Ashkan K; Bleil C; Zebian B; Clark B; Laxton R; King A; Bodi I; Al-Saraj S
    Acta Neurochir (Wien); 2023 Jun; 165(6):1615-1633. PubMed ID: 36929449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
    Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
    Lu VM; Alvi MA; McDonald KL; Daniels DJ
    J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3 G34-mutant high-grade glioma.
    Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH
    Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
    Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
    Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric hemispheric high-grade glioma: targeting the future.
    Coleman C; Stoller S; Grotzer M; Stucklin AG; Nazarian J; Mueller S
    Cancer Metastasis Rev; 2020 Mar; 39(1):245-260. PubMed ID: 31989507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetic signatures of pediatric high-grade glioma: no longer a one-act play.
    Diaz AK; Baker SJ
    Semin Radiat Oncol; 2014 Oct; 24(4):240-7. PubMed ID: 25219808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas.
    Shen H; Yu M; Tsoli M; Chang C; Joshi S; Liu J; Ryall S; Chornenkyy Y; Siddaway R; Hawkins C; Ziegler DS
    Neuro Oncol; 2020 Jan; 22(1):139-151. PubMed ID: 31398252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings.
    Morris M; Driscoll M; Henson JW; Cobbs C; Jiang L; Gocke CD; Chen L; Rodriguez FJ
    J Neuropathol Exp Neurol; 2020 Oct; 79(10):1038-1043. PubMed ID: 32954438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities.
    McNicholas M; De Cola A; Bashardanesh Z; Foss A; Lloyd CB; Hébert S; Faury D; Andrade AF; Jabado N; Kleinman CL; Pathania M
    Cancer Discov; 2023 Jul; 13(7):1592-1615. PubMed ID: 37011011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models.
    Martinez-Velez N; Marigil M; García-Moure M; Gonzalez-Huarriz M; Aristu JJ; Ramos-García LI; Tejada S; Díez-Valle R; Patiño-García A; Becher OJ; Gomez-Manzano C; Fueyo J; Alonso MM
    Acta Neuropathol Commun; 2019 Apr; 7(1):64. PubMed ID: 31036068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
    Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
    Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiological and Immunostaining Characteristics of H3.3 G34R-Mutant Glioma: A Report of 3 Cases and Review of the Literature.
    Onishi S; Amatya VJ; Karlowee V; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pediatr Neurosurg; 2020; 55(5):319-325. PubMed ID: 33227796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characteristics of pediatric high-grade gliomas.
    Chamdine O; Gajjar A
    CNS Oncol; 2014 Nov; 3(6):433-43. PubMed ID: 25438814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.